OEGCX
Price
$19.64
Change
+$0.03 (+0.15%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

OEGCX vs RPTIX

Header iconOEGCX vs RPTIX Comparison
Open Charts OEGCX vs RPTIXBanner chart's image
Invesco Discovery Mid Cap Growth C
Price$19.64
Change+$0.03 (+0.15%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
OEGCX vs RPTIX Comparison Chart
Loading...
VS
OEGCX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OEGCX is a StrongBuy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. OEGCX (6.13B). RPTIX pays higher dividends than OEGCX: RPTIX (0.18) vs OEGCX (0.00). OEGCX was incepted earlier than RPTIX: OEGCX (24 years) vs RPTIX (9 years). OEGCX is a more actively managed with annual turnover of: 124.00 vs. RPTIX (21.70). OEGCX has a lower initial minimum investment than RPTIX: OEGCX (1000) vs RPTIX (500000). OEGCX annual gain was more profitable for investors over the last year : 30.67 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. OEGCX (11.34).
OEGCXRPTIXOEGCX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years9 years-
Gain YTD17.3949.127191%
Front LoadN/AN/A-
Min. Initial Investment10005000000%
Min. Initial Investment IRAN/AN/A-
Net Assets6.13B31.4B20%
Annual Yield % from dividends0.000.18-
Returns for 1 year30.6714.81207%
Returns for 3 years-27.79-13.57205%
Returns for 5 years11.3415.0975%
Returns for 10 years26.14N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp